Treating cattle with progesterone as well as a GnRH analogue affects oestrous cycle length and fertility.
Initiating the chronic administration of progesterone to cattle during metoestrus will produce shortened oestrous cycles containing one or two wave-like sequences of ovarian follicle development. Conception rates are reduced to inseminations at the oestrus preceding these shortened cycles. In contrast, a single injection of the GnRH analogue, buserelin, around mid-dioestrus can lengthen the oestrous cycle by increasing the proportion of cycles with three waves of follicular development and may also increase conception rates. A series of trials was conducted to test the hypothesis that the adverse effects of progesterone on oestrous cycle length and conception rate could be prevented with a strategic injection of GnRH. In Trial 1, progesterone was administered per vaginum to heifers for 10 days from Day 2 or 3 (Oestrus = Day 0) and with (n = 42) or without (n = 46) an injection of a GnRH analogue (10 microg buserelin) on Day 12 or 13. Other heifers (n = 44) served as an untreated control group. The average inter-oestrous interval (IOI) for those heifers treated only with progesterone was 17.0 days and was less (p<0.05) than the average intervals for those also receiving GnRH (20.2 days) or in the control group (20.0 days). In Trial 2, 45 heifers were inseminated following a synchronised oestrus. Progesterone was administered as in Trial 1 to 22 of the heifers. Their conception rate was 45.4% and this was less (p<0.05) than the 73.9% obtained with their 23 untreated contemporaries. Trial 3 was completed using 530 cows in commercial dairyherds. The 259 cows receiving progesterone and GnRH (buserelin) after their first inseminations had a conception rate of 68.3% compared to 56.1% for their 271 untreated herdmates (p<0.05%). Heifer calves born to treated cows had heavier birthweights (33.4 vs. 31.1 kg; p<0.05), but birthweights of bull calves were unaffected (35.5 vs. 35.8 kg). Gestation lengths for cows conceiving to first inseminations were similar for treated and control groups (280.9 vs. 280.5 days). The results of these trials confirmed the hypothesis that a strategic injection of the GnRH analogue, buserelin, could prevent the reductions in oestrous cycle length and conception rate associated with the chronic metoestrous administration of progesterone.
Lynch
P R
PR
Livestock Improvement, Hamilton, New Zealand.
Macmillan
K L
KL
Taufa
V K
VK
D000282:Administration, Intravaginal; D000818:Animals; D000831:Animals, Newborn; D001724:Birth Weight; D002064:Buserelin / Q000008:administration & dosage / Q000494:pharmacology*; D002417:Cattle / Q000502:physiology*; D004971:Estrus / Q000187:drug effects* / Q000502:physiology; D005260:Female; D005298:Fertility / Q000187:drug effects*; D005300:Fertility Agents, Female / Q000008:administration & dosage / Q000494:pharmacology*; D007987:Gonadotropin-Releasing Hormone / Q000627:therapeutic use; D008297:Male; D006080:Ovarian Follicle / Q000502:physiology; D011247:Pregnancy; D018873:Pregnancy Rate; D011374:Progesterone / Q000008:administration & dosage / Q000097:blood / Q000494:pharmacology*
D005300:Fertility Agents, Female; D007987:Gonadotropin-Releasing Hormone; D011374:Progesterone; D002064:Buserelin